Clinical trial
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in…
NCT02531841 · University Hospital Freiburg, Other · Unknown status
Key facts
| NCT number | NCT02531841 |
|---|---|
| Title | High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma |
| Official title | High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial |
| Acronym | MATRix |
| Lead sponsor | University Hospital Freiburg, Other |
| Collaborators | German Federal Ministry of Education and Research International Extranodal Lymphoma Study Group (IELSG) |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diffuse Large B-cell-lymphoma |
| Intervention type | Drug |
| Interventions | Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®), Arm B (TEPADINA®-CARMUBRIS®-Busilvex®) |
| Enrollment | 250 |
| Start date | Jul 1, 2014 |
| Primary completion | Nov 1, 2017 |
| Completion | Dec 1, 2019 |
| First posted | Aug 25, 2015 |
| Last update posted | Aug 25, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: